LRRD1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: LRRD1

NCBI ID: G401387

LRRD1

Other Name(s): LRRD1_HUMAN | leucine rich repeats and death domain containing 1 | Leucine rich repeats and death domain containing 1, transcript variant 1 | Leucine-rich repeat and death domain-containing protein 1 (isoform 1) | Leucine-rich repeat and death domain-containing protein LOC401387 | Leucine-rich repeat and death domain-containing protein 1 | leucine-rich repeat and death domain-containing protein LOC401387 | LRRD1 variant 1

LRRD1: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

LRRD1 (long non-coding RNA-protein 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRRD1 is expressed in most tissues and cells of the human body and is involved in various cellular processes, including cell adhesion, migration, and survival.

The LRRD1 gene has been identified in numerous studies as a potential drug target due to its involvement in various cellular processes that are related to disease progression. For example, LRRD1 has been shown to be involved in cell adhesion, which is critical for the development and progression of cancer. LRRD1 has also been shown to be involved in cell migration, which is a critical process for the development of neurodegenerative diseases. In addition, LRRD1 has been shown to play a role in cell survival, which is critical for the development and progression of many diseases, including cancer and neurodegenerative diseases.

LRRD1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LRRD1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that LRRD1 may be a useful biomarker for the development and progression of these diseases. In addition, LRRD1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that LRRD1 may be a useful biomarker for the development and progression of these diseases.

LRRD1 is also involved in various cellular processes that are related to the immune system. For example, LRRD1 has been shown to play a role in the regulation of T cell activity, which is critical for the immune response. In addition, LRRD1 has been shown to play a role in the regulation of immune cell survival, which is critical for the development and progression of many diseases, including cancer.

In conclusion, LRRD1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. LRRD1 is involved in various cellular processes that are related to disease progression, including cell adhesion, migration, and survival. In addition, LRRD1 has been shown to play a role in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders, making it a promising target for drug development. Further research is needed to fully understand the role of LRRD1 in these diseases and to develop effective treatments.

Protein Name: Leucine Rich Repeats And Death Domain Containing 1

The "LRRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets